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❚ Chlamydia. Of the 4 studies that evaluat-
ed expedited partner treatment for chlamydia, 
1 cohort study showed a statistically signifi cant 
decrease in recurrent or persistent chlamydial 
infection in index patients.2 One RCT showed 
a statistically signifi cant reduction in recurrent 
or persistent urethritis, but didn’t report persis-
tent and recurrent gonorrheal and chlamydial 
infections separately.3 Two RCTs showed a de-
crease in recurrent or persistent chlamydial in-
fection in the index patient, but the diff erence 
didn’t reach statistical signifi cance.4,5
❚ Gonorrhea. Two RCTs evaluated expe-
dited partner treatment for gonorrhea com-
pared with patient referral. One demonstrated 
a statistically signifi cant decrease in persistent 
or recurrent gonococcal infection.5 Th e other 
showed a statistically signifi cant decrease in 
recurrent or persistent urethritis, but without 
identifying recurrent gonorrheal and chla-
mydial infections separately.3
 Should you test or treat partners 
of patients with gonorrhea, 
chlamydia, or trichomoniasis?
Evidence summary
Treating partners of patients with sexually 
transmitted infection has been a core com-
ponent of therapy since the 1940s. Tradition-
ally, partners have been referred to a health 
care provider (by the index patient, the pro-
vider, or a public health offi  cer) for evalua-
tion before being treated. Current methods 
of partner referral reach only 40% to 60% of 
named sexual partners.1 
Expedited partner therapy 
vs traditional patient referral
Success of treatment is most readily measured 
by a reduction in the persistence or recurrence 
of infection in the index patient. Four RCTs and 
1 observational cohort study have compared 
traditional patient referral with expedited part-
ner treatment.2-6 Th e primary outcome measure 
in all studies was reduction of persistent or re-
current infection in the index patient (TABLE 1). 
EVIDENCE-BASED ANSWER
A generally speaking, treating  partners empirically is as ef-
fective or more eff ective than traditional 
referral and testing. Empiric treatment of 
partners of female or heterosexual male 
patients diagnosed with gonorrhea or chla-
mydia using expedited partner therapy 
(having the index patient deliver therapy to 
the partner) decreases the risk of persistent 
or recurrent infection in the index patient 
(strength of recommendation [SOR]: A, meta-
analysis). Th e eff ect is greater for gonorrhea 
than chlamydia. 
By contrast, expedited partner therapy 
for trichomoniasis appears equivalent to a 
test-fi rst approach (SOR: B, single random-
ized controlled trial [RCT]). 
No studies have evaluated empiric 
treatment of chlamydia, gonorrhea, or 
trichomoniasis in men who have sex with 
men. State laws vary with regard to expe-
dited partner therapy and should be con-
sidered. Moreover, this type of empiric 
therapy misses the opportunity to coun-
sel partners and treat comorbid disease, if 
present. 
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❚ Trichomoniasis. One RCT compared 
expedited partner therapy with patient refer-
ral for patients with trichomoniasis. Th e study 
didn’t show a statistically signifi cant diff er-
ence in recurrent or persistent infection. 
The verdict: 
Expedited partner therapy 
works better
A meta-analysis of the above studies evaluated 
the eff ect of expedited partner therapy com-
pared with patient referral on the rate of recur-
rent or persistent gonorrhea, chlamydia, and 
trichomoniasis and the number of partners 
treated per index patient.1 Empiric therapy 
was associated with a lower rate of recurrent 
or persistent infections (risk ratio [RR]=0.73; 
95% confi dence interval [CI], 0.57-0.93) and a 
higher number of partners treated per patient 
(RR=1.44; 95% CI, 1.12-1.86). 
Take state law into account
Providers need to consider their state’s laws 
regarding empiric partner therapy. A state-by-
state evaluation of the legal status of expedited 
partner therapy is available on the Centers for 
Disease Control and Prevention’s Web site, 
and is summarized in TABLE 2.7
Recommendations
A review of expedited partner therapy by the 
Centers for Disease Control and Prevention 
concluded: “Th e evidence indicates that ex-
pedited partner therapy should be available 
to clinicians as an option for partner man-
agement … [but it] does not replace other 
strategies such as standard patient referral 
or provider-assisted referral, when available. 
...   Expedited partner therapy should be ac-
TABLE 1
Traditional patient referral vs expedited partner treatment:
How the 2 compare 
Patient population Design Outcomes
Favored treat-
ment: PDPT vs PR P value NNT
Heterosexual men 
with N gonorrhoeae
or C trachomatis2
RCT Recurrent/persis-
tent N gonorrhoeae 
or C trachomatis
PDPT <.001 5
Women with 
C trachomatis3
RCT Recurrent/persis-
tent C trachomatis
PDPT .11 33.3
Women and 
heterosexual men 
with N gonorrhoeae
or C trachomatis4
RCT Recurrent/persis-
tent N gonorrhoeae
PDPT .01 12.5
Recurrent/persis-
tent C trachomatis
PDPT .17 50
Women with 
T vaginalis5
RCT Recurrent/persis-
tent T vaginalis
PR .64 32.3
Women with 
C trachomatis6
Observational 
cohort
Recurrent/persis-
tent C trachomatis
PDPT <.05 7.1
C trachomatis, Chlamydia trachomatis; N gonorrhoeae, Neisseria gonorrhoeae; NNT, number needed to treat; PDPT, patient delivered partner therapy; 
PR, patient referral; RCT, randomized controlled trial; T vaginalis, Trichomonas vaginalis.
TABLE 2
What’s the status of expedited
partner therapy (EPT) in your state?7
EPT is permissible in 20 states: Arizona, California, Colorado, Illinois, 
Iowa, Louisiana, Minnesota, Mississippi, Nevada, New Hampshire, 
New Mexico, New York, North Dakota, Oregon, Pennsylvania, Tennessee,
Texas, Utah, Washington, and Wyoming. (EPT is also permissible in 
Baltimore, MD.)
EPT is potentially allowable in 21 states: Alabama, Alaska, Connecticut, 
Delaware, Georgia, Hawaii, Idaho, Indiana, Kansas, Maine, Maryland,
Massachusetts, Missouri, Montana, Nebraska, New Jersey, North Carolina, 
Rhode Island, South Dakota, Virginia, and Wisconsin. (EPT is also potentially 
allowable in the District of Columbia and Puerto Rico.)
EPT is prohibited in 9 states: Arkansas, Florida, Kentucky, Michigan, Ohio,
Oklahoma, South Carolina, Vermont, and West Virginia. 
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companied by information [advising] recipi-
ents to seek personal health care in addition 
to expedited partner therapy. Expedited 
partner therapy has a limited role in partner 
management for trichomoniasis. No data 
support its use in the routine management 
of syphilis, and there is no experience with 
expedited partner therapy for gonorrhea or 
chlamydial infection among men who have 
sex with men.”8
Neither the American Academy of Family 
Physicians nor the American College of Obste-
tricians and Gynecologists has issued a policy 
statement on expedited partner therapy.  
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